(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares
Filed with SSE · Stock code 600276 · · 2 pages · Chinese
Summary by 6ix AI
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced progress on its A-share repurchase plan. The company has repurchased a small percentage of its total shares, with details on the number of shares and the price range provided. The announcement includes compliance with relevant regulations and a commitment to continue the repurchase based on market conditions.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Story so far
Earlier from Jiangsu Hengrui Pharmaceuticals
- Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces EMA Validation of Marketing Authorisation Application for Wevdury (fuzuloparib) in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer
- Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Initial Repurchase of the Company's A-Shares
- Notice on Convening the 1st Extraordinary General Meeting in 2026
Later from Jiangsu Hengrui Pharmaceuticals
All Jiangsu Hengrui Pharmaceuticals news releasesFollow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals